PICI Network In the News | Recent Highlights
Parker Institute for Cancer Immunotherapy
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases
The?Parker Institute for Cancer Immunotherapy?(PICI) is committed to turning all cancers into curable diseases faster, with a relentless focus on science, collaboration, patients and bold action. The PICI Network gives life to this pursuit, pushing novel immunotherapy research forward with partnerships, events, awards and individual accomplishments.
Every month, we?round?up?PICI Network?news?to highlight collaborations between researchers, nonprofits and industry, highlighting the impact of our collective pursuits on the field.
Read on for?recent achievements.?
Research Advances?
STAT | Oct. 4, 2022
Researchers are beginning to work out why more than half of lymphoma patients treated with CAR-T therapy don’t experience lasting remission, depending on the product.
The article covers these Nature Medicine papers:
Memorial Sloan Kettering Cancer Center | Oct. 13, 2022
A newly discovered class of immune cell — Thetis cells — plays a key role in establishing a harmonious relationship between infants and the helpful microbes in their digestive systems. The work also raises the possibility of roles for Thetis cells in tolerance to other types of foreign antigens, as well as self-antigens, which could be important for cancer immune responses.
The University of Texas MD Anderson Cancer Center | Oct. 26, 2022
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, MD Anderson researchers?report.
MedPage Today | Oct. 27, 2022
In a study funded in part by PICI, researchers at Memorial Sloan Kettering compared oncologic outcomes and genomic alteration profiles in glandular variants in bladder cancer, potentially shedding new light on more effective treatments.
Industry News
BioPharma Dive | Oct. 18, 2022
The University of Pennsylvania immunologist and Kymriah inventor spoke with BioPharma Dive about working with pharma, starting companies and the future of cell therapy.
3T Biosciences | Oct. 25, 2022
John Leonard, MD, president and CEO of Intellia Therapeutics, joins the board of the PICI-backed biotech.
STAT | Oct. 26, 2022
Tim Wright and D.A. Wallach have become biotech’s newest odd couple, launching health-care VC firm Time BioVentures, which boasts an eclectic mix of advisers and investors, including Sean Parker and Jim Allison.
领英推荐
Endpoints News | Oct. 26, 2022
Candel Therapeutics is joining forces with Carl June’s lab at the University of Pennsylvania to see if the herpes virus can boost the effectiveness of CAR-T therapies in solid tumors, the biotech led by Paul Peter Tak announced.
Grants & Awards
National Institutes of Health?| Oct. 4, 2022
Two PICI Network members have been awarded?High-Risk, High-Reward Research program?grants from the NIH in recognition of unconventional, boundary-pushing work focused on challenges in biomedical research.
Recipients of the?Transformative Research Awards?are:
National Academy of Medicine | Oct. 17, 2022
The Parker Institute for Cancer Immunotherapy congratulates Crystal Mackall, MD, for her election to the National Academy of Medicine. Dr. Mackall is recognized for “pioneering immune therapies for children’s cancers, and for discovering fundamental principles of human immunology and translating these insights into cutting-edge engineered cell therapies for cancer.”
Read the Stanford Medicine press release?here.
Center News
University of California, San Francisco | Oct. 7, 2022
First Lady Jill Biden, PhD, met with top UC San Francisco cancer leaders during a visit to hear about the institution’s breast cancer research and progress on the National Cancer Moonshot.
Dana-Farber Cancer Institute | Oct. 28, 2022
Dana-Farber and Laurie Glimcher, MD, president and CEO, are No.1 on the 2022 Top 100 Women-Led Businesses in Massachusetts list.
Research Meetings
Pharmacy Times | Oct. 5, 2022
In two interviews recorded at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference, Yvonne Chen, PhD, of UCLA discusses:
Parker Institute for Cancer Immunotherapy | Oct. 21, 2022
PICI Network investigators will present the latest in immuno-oncology research at the 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer, Nov. 8-12 in Boston and online.